Akaal Pharma has completed recruitment for a Phase-2 clinical trial for atopic dermatitis and associated pruritus

June 04, 2024 11:15 PM PDT | By EIN Presswire

Google News:

Akaal Pharma has completed recruitment for a Phase-2 clinical trial for atopic dermatitis and associated pruritus — Image source: EIN Presswire

Recent News

S&P 500 nears record high despite headwinds: key drivers behind the su...

Australia sues China-linked firm over rare earths stake breach

Eli Lilly seen as the stronger bet amid escalating competition with No...

Why US shale oil production is likely to see no upside this year?

GREATER SHEPPARTON, VICTORIA, AUSTRALIA, June 5, 2024 /EINPresswire.com/ -- Akaal Pharma Pty Ltd has completed recruitment for a Phase-2 clinical trial involving patients with atopic dermatitis and associated pruritus.

Akaal Pharma Pty Limited (Akaal) today announced that it has completed recruitment of 140 patients for its Phase 2 clinical study to evaluate safety, tolerability and efficacy of topical 1% AKP-119 in atopic dermatitis participants with pruritus. The Phase 2 clinical study is a multicentre, randomized, double blind, placebo-controlled, two-arm study.

Akaal anticipates top-line data of the Phase 2 clinical study in Q3/4 of 2024. The Phase 2 clinical study targeted patients with atopic dermatitis patients that have mild to moderate disease with at least one lesion of moderate to severe pruritus.

This study follows a successful Phase-1a/1b clinical study Akaal completed on atopic dermatitis and psoriasis patients that showed AK-119 to be safe, well tolerated with clear signals of efficacy in relieving inflammation and disease score.

Atopic dermatitis is one form chronic skin inflammation where the associated pathology of pruritus largely impacts the patient’s quality of life. Akaal’s lead candidate, AK-119, is a broad action, differentiated S1P1 modulator able to downregulate multiple inflammatory, pain and pruritus factors with significant anti-inflammatory efficacy in the preclinical and in humans.

As well as topical applications, Akaal has been exploring the potential of AK-119 to be delivered orally. Akaal has completed a further Phase-1 clinical study in 40 healthy volunteers to evaluate the safety profile of AK-119 when administered orally. The results of the study showed no bradycardia/dyspnoea and mild lymphopenia (immune suppression), recovering to baseline within 24 hrs after multiple day dosing.

Akaal has shown its lead candidate, AK-119, has potential applications in several inflammatory/immune indications as well as an alternative for pain management. AK-119 has showed oral efficacy in animal models of neuropathic pain and the Phase-1 clinal study demonstrated safety and potentially targeting S1P1 area could have applications in neuropathic pain.

“At Akaal we continue to actively prioritize and expand our developmental programs to bring new and effective treatments into the market,” said co-CEO of Akaal Pharma Dr Antonio Rajic.

About Akaal Pharma Pty Ltd: Akaal Pharma is a private, clinical-stage, Australian biotechnology company focused on advancing its internally discovered topical and oral programs for the treatment of inflammatory/immune skin indications and pain indications. For more information, please visit www.akaalpharma.com

Contacts: Akaal Pharma Pty Ltd, 89 School Road, Shepparton East, VIC-3631, Australia. Tel: +61348008992. Email: [email protected]

Disclaimer: Certain statements in this new release concerning Akaal Pharma business are considered “forward looking statements”. Any or all the forward-looking statements in this press release can be affected by inaccurate assumptions. Akaal Pharma undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

B Sandhu
Akaal Pharma Pty Ltd
+44 7772 226665
email us here

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.